Join our daily newsletter At The Bell to receive exclusive market insights
- Australian Dairy Nutritionals (AHF) confirms its application to the US Food and Drug Administration to facilitate accelerated approval for its future Gradulac Gentle infant formula range
- The board is working with both Australian and American authorities to progress supply opportunities into the US market following a critical shortage of baby formula
- The shortage of the product comes after one of the country’s top baby formula makers, Abbott Laboratories, closed its manufacturing plant
- The dairy group said it has inventory available as well as inventory scheduled for production in June 2022
- AHF shares are down 9.20 per cent, trading at 7.9 cents at market close
Australian Dairy Nutritionals (AHF) confirmed it has applied to the US Food and Drug Administration (FDA) for an enforcement discretion to facilitate accelerated approval for its future Gradulac Gentle infant formula range.
The board has been working with both Australian and American authorities to progress supply opportunities in the US market following a critical shortage of baby formula across the country.
The shortage of the product comes after one of the country’s top baby formula makers, Abbott Laboratories, closed its manufacturing plant.
In certain states like New York, the Mayor had declared a state of emergency on the state to help crack down price gouging.
The dairy group said it has inventory available as well as inventory scheduled for production in June 2022.
Just last week, the company had reported its first successfully produced milk powders at its new infant formula plant in Victoria.
AHF’s next steps include refining operational parameters and resultant powders as well as undertaking infant formula production trials.
The first commercial production of its organic A2 infant formula is scheduled for June with availability in Chemist Warehouse stores targeted for H2 FY22.
AHF shares were down 9.20 per cent, trading at 7.9 cents at market close.
